ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.
Here is the original post:
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and...
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
Visit link:
argenx Highlights 2024 Strategic Priorities
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance
Read more:
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
Continued here:
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
January 8, 2024 – release at 7:30 am CETSophia Antipolis, France
Read the original post:
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET
Here is the original post:
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Go here to read the rest:
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Cumulus Oncology raises £9m in seed financing
Visit link:
Cumulus Oncology raises £9m in seed financing